TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer‐specific apoptosis within a therapeutic window
Ronald Koschny, Tom M. Ganten, Jaromir Sykora, Tobias L. Haas, Martin R. Sprick, Armin Kolb, Wolfgang Stremmel, Henning Walczak – 26 February 2007 – Tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL) represents a novel promising anticancer biotherapeutic. However, TRAIL‐resistant tumor cells require combinatorial regimens to sensitize tumor but not normal cells for TRAIL‐induced apoptosis.